OBJECTIVE: Cure rate models are survival models, commonly applied to model survival data with a cured fraction. In the existence of a cure rate, if the distribution of survival times for susceptible patients is specified, researchers usually prefer cure models to parametric models. Different distributions can be assumed for the survival times, for instance, generalized modified Weibull (GMW), exponentiated Weibull (EW), and log-beta Weibull. The purpose of this study is to select the best distribution for uncured patients' survival times by comparing the mixture cure models based on the GMW distribution and its particular cases.
MATERIALS AND METHODS: A data set of 91 patients with high-risk acute lymphoblastic leukemia (ALL) followed for five years from 1982 to 1987 was chosen for fitting the mixture cure model. We used the maximum likelihood estimation technique via R software 3.6.2 to obtain the estimates for parameters of the proposed model in the existence of cure rate, censored data, and covariates. For the best model choice, the Akaike information criterion (AIC) was implemented.
RESULTS: After comparing different parametric models fitted to the data, including or excluding cure fraction, without covariates, the smallest AIC values were obtained by the EW and the GMW distributions, (953.31/969.35) and (955.84/975.99), respectively. Besides, assuming a mixture cure model based on GMW with covariates, an estimated ratio between cure fractions for allogeneic and autologous bone marrow transplant groups (and its 95% confidence intervals) were 1.42972 (95% CI: 1.18614 - 1.72955).
CONCLUSION: The results of this study reveal that the EW and the GMW distributions are the best choices for the survival times of Leukemia patients.
.
Stat Med. 1984 Apr-Jun;3(2):153-63
[PMID:
6463452]
Comput Methods Programs Biomed. 2013 Dec;112(3):343-55
[PMID:
24008248]
Biometrics. 2000 Mar;56(1):227-36
[PMID:
10783800]
Biometrics. 1982 Dec;38(4):1041-6
[PMID:
7168793]
Br J Cancer. 2003 Aug 18;89(4):605-11
[PMID:
12915864]
Blood Cancer J. 2017 Jun 30;7(6):e577
[PMID:
28665419]
Stat Med. 1998 Apr 30;17(8):813-30
[PMID:
9595613]
N Engl J Med. 1987 Aug 20;317(8):461-7
[PMID:
3302708]
Br J Cancer. 2003 Aug 4;89(3):431-6
[PMID:
12888808]
Stat Med. 2001 Jun 30;20(12):1783-96
[PMID:
11406841]
Stat Sin. 2010;20:661-674
[PMID:
20414460]
Comput Methods Programs Biomed. 2012 Dec;108(3):1255-60
[PMID:
23017250]
Stat Med. 1995 Jan 15;14(1):39-49
[PMID:
7701157]
Stat Med. 2009 Feb 1;28(3):510-24
[PMID:
19003981]